| Title: | Does insulin-like growth factor moderate the association between height and risk of cancer at 24 sites? |
| Journal: | British Journal of Cancer |
| Published: | 14 Sep 2020 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/32921791/ |
| DOI: | https://doi.org/10.1038/s41416-020-01059-1 |
| URL: | https://www.nature.com/articles/s41416-020-01059-1.pdf |
Publication 4729
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundWhether the association of height with cancers differs by insulin-like growth factors has not been fully elucidated. Therefore, this study aimed to investigate the sex-specific associations between height and 24 site-specific cancers and to assess whether the association differed by IGF-1.MethodsIn total, 414,923 participants from the UK Biobank prospective cohort study were included. The association of height (per 5-cm increment) with incidence and mortality from 24 cancer sites was investigated by using Cox proportional hazard models.ResultsThe median follow-up was 6.0 years. In men, height was positively associated with incidence risk of all-cause cancer and at five sites (lung, lymphatic, leukaemia, non-Hodgkin lymphoma and melanoma). In women, it was associated with breast, melanoma, lymphatic, non-Hodgkin lymphoma and all-cause cancer. The association was stronger in women than men for all-cause cancer incidence. The strength of the association did not differ by IGF-1 concentration.ConclusionsAdult height was associated with risk of several cancer sites. However, some of these associations were sex-specific. There was no strong evidence to support IGF-1 moderating the association between height and cancer.</p>
4 Authors
- Solange Parra-Soto
- Frederick K. Ho
- Jill P. Pell
- Carlos Celis-Morales
Enabling scientific discoveries that improve human health